In January, The Lancet journal published studies showing that across 4 trials, faricimab improved and maintained vision in two leading causes of vision loss and reduced time between treatments. In this episode, we examine the results and implications of the research in an expert discussion chaired by Prof Anat Loewenstein (Tel Aviv Medical Centre) and Prof Reinier Schlingemann (Amsterdam University and Jules Gonin). They are joined by Ramin Tadayoni (Paris University), Professor Sandrine Zweifel (University Hospital Zurich) and Professor Usha Chakravarthy (Queen's University Belfast)